ProAct Study: New Features of Insulin Pumps Improve Diabetes Management and Glycemic Control in Patients after Transition of Continuous Subcutaneous Insulin Infusion Systems

Authors:

Abstract
Background: Continuous subcutaneous insulin infusion (CSII) patients experience switches of pump systems on a regular basis. We investigated the impact of transition from older pumps to the Accu-Chek ® Combo system (Roche Diagnostics Deutschland GmbH, Mannheim, Germany) on a patient's glycemic control and diabetes management. Patients and Methods: In total, 299 patients (172 female, 127 male; mean±SD age, 39.4±15.2 years; CSII duration, 7.0±5.2 years) were enrolled by 61 European sites into this uncontrolled prospective trial. Glycemic control, safety, and diabetes management parameters were measured at baseline and after 3 and 6 months. Changes from baseline were analyzed. Results: After transition to the new insulin pump, mean±SD hemoglobin A1c (HbA1c) values decreased from 7.8±1.1% (baseline) to 7.7±1.1% (end point). The proportion of patients with HbA1c 8.0% decreased (baseline, 36.2%; end point, 32.7%; P P n =48) had a larger HbA1c decrease (–0.40%) than long-term (≥3 years) users ( n =251) (–0.07%; P P P <0.05) during the study. Conclusions: Transition from older pump systems to the Accu-Chek Combo system in a large patient population resulted in stable glycemic control with significant improvements in HbA1c in patients with unsatisfactory baseline HbA1c and shorter pump use. Increased frequency of self-monitoring of blood glucose and decrease of bolus frequency could suggest a more confident diabetes management and a reduced need for correction boluses.

This publication has 21 references indexed in Scilit: